CORD-19:cb16d307afaecebd683e6d74c8b501ed54b0c9a4 / 52507-52893 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T303","span":{"begin":0,"end":386},"obj":"Sentence"},{"id":"T91220","span":{"begin":0,"end":386},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In 2007, Kimata and co-workers [118] reported the synthesis and assessment of multiple PrP-res accumulation inhibitors according to the structure of edaravone, in which the most potent compound 163 (Fig. 16 ) displayed PrP-res inhibitory effect in the ScN2a cells with IC 50 value of 3 nM, which was 130 times more active than quinacrine and more than 300-fold effective than edaravone."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T17","span":{"begin":0,"end":386},"obj":"Sentence"}],"text":"In 2007, Kimata and co-workers [118] reported the synthesis and assessment of multiple PrP-res accumulation inhibitors according to the structure of edaravone, in which the most potent compound 163 (Fig. 16 ) displayed PrP-res inhibitory effect in the ScN2a cells with IC 50 value of 3 nM, which was 130 times more active than quinacrine and more than 300-fold effective than edaravone."}